Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer’s Disease. Review of Reviews

Alzheimer’s disease (AD) is the most common form of dementia over the age of 65. It is estimated that 115.4 million people will be affected by AD by 2050. Acetylcholinesterase inhibitors (AChEI) are the only available and approved treatment for AD. The aim of the present study was to analyse the evi...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreta, Marta Pérez-Gómez, Burgos-Alonso, Natalia, Torrecilla, María, Marco-Contelles, José, Bruzos-Cidón, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615650/
https://www.ncbi.nlm.nih.gov/pubmed/34829917
http://dx.doi.org/10.3390/biomedicines9111689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615650/
https://www.ncbi.nlm.nih.gov/pubmed/34829917
http://dx.doi.org/10.3390/biomedicines9111689

Ejemplares similares